GeneDx Holdings [WGS] — Catalyst Calendar
Task 6 · investment-memo v1.4.2 · built 2026-07-29 · spot $60.54 (close 2026-07-27, as used throughout the memo)
Verdict this calendar serves: Watchlist — research direction NEGATIVE / short-biased, not actionable.
Short gates 4 and 5 fail; long gates 1, 2 and 6 fail. Nothing here is an entry instruction. Every entry carries an
explicit upgrade/downgrade threshold, and the thresholds are lifted verbatim from the invalidation triggers already
recorded in WGS_Trade_Construction.md §3 and §7 — this calendar does not create new ones.
Scope note, stated plainly. This calendar was built on 2026-07-29 from the deliverables produced on 2026-07-27. No new research was run to produce it — no new filings, no new price data, no new consensus pull. Every date below is either (a) company-confirmed in the source documents, (b) explicitly labelled an estimate with its basis stated, or (c) explicitly labelled NOT ANNOUNCED. Nothing has been guessed. The named absences in §4 are part of the output, not an apology for it.
1. The one that matters
2026-08-03 (Monday), after market close — Q2-2026 results · call 4:30pm ET · CRITICAL
Five days away. Company-confirmed (source recorded in WGS_Research.md §10 as company IR / BioSpace; carried
into WGS_Trade_Construction.md §2.3). This is the Gate 3 catalyst, and it is unusually clean: it does not merely
sit near the position, it discloses the exact metric in dispute.
GeneDx reports exome & genome revenue and exome & genome test-result volume in the 8-K Item 2.02 exhibit every
quarter. ASP is therefore directly computable on the day — it is not disclosed, it is derived, and the memo has
derived it for nine consecutive quarters already (WGS_Model.xlsx, sheet KPI_ASP, row 8).
The single number to compute at 4:05pm ET:
Q2-2026 ASP = exome & genome revenue ($) ÷ exome & genome test-result volume
Benchmarks it must be read against — all four are already in the file:
| Benchmark | Value | Where it comes from |
|---|---|---|
| Q1-2026 actual | $3,296 | Computed, KPI_ASP J8 |
| Q2-2026 as guided | ~$3,333 | $100m E&G revenue ÷ ~30,000 tests, the company's own Q2 guide |
| H2-2026 required to hit the reset FY guide | $3,506 | KPI_ASP B31 — the variant |
| 25Q3 peak | $3,848 | KPI_ASP H8 |
| Q2 ASP prints… | Read | Action |
|---|---|---|
| ≥ $3,450 | The price deterioration is arresting | DOWNGRADE the negative research view. Trigger already recorded in Trade §3 |
| $3,333 ± ~2% | In line with guide. Resolves nothing on its own — the H2 step-up question survives to the Q3 print | Hold Watchlist, negative bias intact |
| < $3,250 | Mechanism confirmed — mix, not a one-quarter true-up | Short-side confirmation. But see §3: confirmation alone does not fix Gate 4 or Gate 5. Do not convert |
Three further items resolve on the same release, and all three are in the memo's invalidation set:
| Item | Baseline | Upgrade threshold | Downgrade threshold |
|---|---|---|---|
| FY2026 guidance action | Reset 2026-05-04 to $475–490m from $540–555m | Raised above $490m, or E&G revenue growth guided above 25% → the negative view is wrong | A second consecutive cut → mechanism confirmed |
| Whether the +5.7% H2 ASP step-up is defended | No mechanism stated in the release, the 10-Q, or any subsequent 8-K | A named, specific mechanism (contracted rate increases, payer wins, reflex reimbursement clarified) → the variant weakens materially; Gate 2 was already MARGINAL and would likely fail | Reaffirmed with no mechanism → the variant stands |
| Accounts receivable / DSO (Q2 10-Q) | 67.7 days, up from 36.2 five quarters ago; AR +67% YoY | DSO < 55 days → the receivables build was a timing artifact, not a collections problem. The earliest hard signal in the file is invalidated | DSO > 70 → collections are still lagging the accrual |
Confounder, disclosed rather than buried. The securities class-action lead-plaintiff deadline is also
2026-08-03 (WGS_Research.md §9). Litigation headlines can move the stock independently of the operating result
on exactly that day. Do not attribute the whole print-day move to the numbers.
Do not trade the print. Front-week IV was 148–164% on 2026-07-27, ~2.1x 30-day realised (72.2%), with a 41% bid/ask on the Aug-7 $60 put and a 19.9% implied move against a print-day history of −49.2% (5 May 2026), −7.3% (24 Feb 2026), −4.2% (29 Oct 2025). Gate 5 fails on precisely this. The correct use of 3 August is to buy the information for free by waiting one week, which is the argument made in Trade §5.
2. Dated calendar
Estimated dates are marked ~ and carry their basis. Dates the company has not announced are marked NOT ANNOUNCED rather than being interpolated into a false precision.
| Date | Event | Confidence | Importance | Upgrade threshold | Downgrade threshold |
|---|---|---|---|---|---|
| 2026-08-03 | Q2-2026 results, after close (call 4:30pm ET) | Company-confirmed | CRITICAL | ASP ≥ $3,450, or FY guide raised >$490m | Second guidance cut, or ASP < $3,250 |
| 2026-08-03 | Securities class action — lead-plaintiff deadline | Confirmed in file | MEDIUM | — | A named institutional lead plaintiff → the case is durable, not nuisance. Confounds the same day's price action |
| ~2026-08-03 to mid-Aug | Q2-2026 Form 10-Q — carries AR (→DSO), third-party payor reserves, Fabric residual intangibles, Blackstone loan terms | Estimated. Basis: the Q1-2026 10-Q was filed 2026-05-04, the same day as the release | HIGH | DSO < 55 days | DSO > 70; payor reserve above $6.0m again |
| 2026-08-07 | Front-week options expiry — the first expiry that captures the print | Confirmed (Alpaca chain, 2026-07-27) | LOW | — | Informational only. Not a vehicle — see §1 |
| ~Aug–Sep 2026 | Semi-monthly FINRA short-interest settlements | Cadence confirmed; individual settlement dates NOT ANNOUNCED in this file | HIGH for Gate 5 | Short interest falls below ~20% of float → the Gate 5 crowding veto is fixed. This is one of the three conditions in the short-conversion test | Rises above ~35% of float → more crowded, not less |
| 2026-09-18 | Sep-2026 options expiry — the earliest expiry the memo would consider if the name ever converts | Confirmed (Alpaca chain) | LOW | — | Reference only. The illustrative $50/$40 put spread priced in Trade §6 is not recommended |
| ~late Oct 2026 | Q3-2026 results | Estimated. NOT ANNOUNCED. Basis: the prior-year Q3 print moved the stock on 2025-10-29 | HIGH | Q3 ASP ≥ $3,506 → the H2 step-up is real and the variant is dead | Q3 ASP ≤ H1's $3,315 → arithmetically the FY guide cannot be met; the variant is proven on the second of two H2 quarters |
| ~Nov 2026 | Q3-2026 Form 10-Q | Estimated, same basis | MEDIUM | DSO trend breaks below 55 | Fourth consecutive quarter of DSO expansion |
| ~late Feb 2027 | FY2026 results + FY2027 guidance + 10-K | Estimated. NOT ANNOUNCED. Basis: the FY2025 10-K was filed 2026-02-23 and the print moved the stock 2026-02-24 | CRITICAL | FY2026 revenue lands at or above $475m (the guidance floor) → the house base of $466.8m was wrong and the memo's central number is refuted | FY2026 revenue below $475m → the variant is settled arithmetically. This is the memo's stated full-resolution date |
| ~early May 2027 | Q1-2027 results | Estimated. NOT ANNOUNCED. Basis: Q1-2026 printed 2026-05-04 | MEDIUM | Second consecutive quarter of ASP ≥ $3,450 → one of the two long-conversion conditions is met | — |
3. Price and level triggers (continuous, no event required)
Lifted from WGS_Trade_Construction.md §3 and §7. These are monitoring levels, not orders.
| Level | Meaning | Action |
|---|---|---|
| $92.20 (200-day MA) | Any close above → the tape has fully rejected the reset thesis | The negative research view is wrong. Move to Avoid and stop tracking the short side. Hard invalidation |
| ~$80 | The bear-case gap widens enough to restore a positive net E[R] for a short — fixes Gate 4 | Necessary, not sufficient. Conversion requires all three of (a) ASP < $3,250 or a second cut, (b) short interest < ~20% of float, and (c) this price |
| ~$40 | The bear-case target ($39.15) | Long-conversion price. Necessary, not sufficient — Gate 1 for a long cannot be satisfied by price alone. Requires DSO < 55 days or two consecutive quarters of ASP ≥ $3,450 |
| $60.54 | Spot at underwriting | Reference |
4. Continuous monitoring — no earnings call required
The [UNPUBLISHED] items are the ones that generate lead time: they resolve from free public corpora between prints.
| ID | Item | Baseline (2026-07-27) | Cadence | Trigger |
|---|---|---|---|---|
| W-U1 | Reflex-product reimbursement — is the exome→genome reflex separately paid, bundled, or partially paid? The single largest unquantified ASP risk in the file. Check AMA CPT / CMS CLFS for a distinct code, and the Q2 release for any economics | Not determinable as of 2026-07-27. Announced 2026Q1 with no economics; absent from the 10-Q; no distinct CPT code disclosed | quarterly, plus any CPT release | Any disclosure of separate payment → ASP dilution risk falls. Confirmation of bundling → the mechanism has a second, structural leg |
| W-U2 | pricing / ASP / average selling price / denial / collections in the 8-K Ex-99.1 |
ZERO across 17 consecutive quarters (2022Q1–2026Q1) | every quarter | Any first use → management has started discussing the metric it has never discussed. Re-read the release in full; this would be a genuine disclosure regime change |
| W-U3 | ClinicalTrials.gov query.spons=GeneDx [UNPUBLISHED] |
ZERO GeneDx-sponsored studies. The four gNBS programmes it publicises (Early Check/RTI, GUARDIAN/Columbia, BEACONS, UW ISeqU) are third-party-sponsored, GeneDx the vendor | quarterly | Any first GeneDx-sponsored registration → the company has taken control of its own long-duration option. This is leg 1 of the 2B duration variant, which currently fails at leg 1. Would force a Gate 2 re-underwrite |
| W-U4 | gNBS programme status (Early Check, GUARDIAN, BEACONS, UW ISeqU) [UNPUBLISHED] | Third-party-sponsored; GeneDx does not control the timetable. newborn and NICU mentions both fell to 0.0 in 2026Q1 |
quarterly | Grant renewal, expansion or termination at any sponsor. No readout dates for these are in the file and none has been invented |
| W-U5 | Short interest / float | 5.83m shares = 30.79% of float; 18.94m float; 5.22 days to cover; already declining (5.94m → 5.83m) | semi-monthly (FINRA) | < ~20% of float → Gate 5 crowding constraint clears. > 35% → more crowded |
| W-U6 | Form 4 filings — Casdin Capital, Keith Meister / Corvex | ~$106.6m of clustered open-market code-P buying, six filings, all after the guidance cut, averaging up $35 → $56. The single strongest contrary fact in the file | weekly | Any code-S sale by either → the strongest counter-evidence to the negative view weakens materially. Further buying → it strengthens |
| W-U7 | Schedule 13D/A (Casdin / Meister joint) | Amendments 11 and 12 filed 2026-05-15 and 2026-05-22 | monthly | Amendment 13 — any change in stated purpose (board action, strategic alternatives) |
| W-U8 | Equity issuance — TD Cowen ATM (2024) + S-3ASR shelf (filed 2025-10-28) | Shares 29,245,296 (31-Dec-25) → 29,666,318 (31-Mar-26), +5.6% YoY | quarterly (10-Q cover page) | Any ATM drawdown. At an under-2-year runway on the Q1 burn (−$32.4m operating, −$6.5m capex), issuance is available and cheap to execute |
| W-U9 | Consensus revisions (Alpha Vantage EARNINGS_ESTIMATES) |
FY2026 EPS −107% in 90 days; FY2027 −46%; 5 of 9 cutting FY2027 in 30 days; targets raised by four analysts over the same window | quarterly (respect the shared 25/day cap — one call) | Revisions turn positive → the cleanest short-side factor in the scorecard flips. Any first Sell rating from 9 Buy / 0 Hold / 0 Sell |
| W-U10 | PubMed GeneDx[Affiliation] [UNPUBLISHED] |
118 (2019) → 96 (2024) → 106 (2025) → 59 through Jul 2026 (annualising ~101). Flat for five years | semi-annual | Full-2026 > 130 → the scientific moat is genuinely widening, not a cumulative-stock claim |
| W-U11 | PubMed rare-disease sequencing literature [UNPUBLISHED] | 142 (2022) → 146 (2025) → 106 through Jul 2026 (annualising ~180) | semi-annual | Full-2026 < 146 → adoption is stalling, which would undercut the volume leg the bull case needs |
| W-U12 | Management / commercial leadership | Mark Gardner, President from 2026-06-15 (ex-Quest SVP Molecular Genomics & Oncology), explicit remit over "lab and commercial operations". 3 August is his first earnings call | quarterly | Any 8-K Item 5.02 departure (Stueland, Feeley, Gardner) → the remediation thesis changes. Gardner departing would be a severe negative |
| W-U13 | Legacy Sema4 third-party payor matters | Reserve $5.0m → $6.0m in Q1-2026; a $2.0m overpayment settlement was due June 2026 | quarterly | Confirm in the Q2 10-Q that the $2.0m settled. Reserve rising again → the legacy tail is not closed |
| W-U14 | Price alert | Spot $60.54 | daily | $92.20 → hard invalidation, move to Avoid. ~$80 → Gate 4 review. ~$40 → long-conversion review |
5. What this calendar could NOT source — stated, not omitted
Per the standing rule that a "not disclosed" finding is a research task rather than a limitation to apologise for, and because a fabricated date in a catalyst calendar is worse than an absent one:
| Item | Status | Why it is absent |
|---|---|---|
| Any dated reimbursement or coverage decision | NONE EXISTS IN THE FILE | There is no pending CMS national coverage determination, no dated payer decision, and no scheduled CPT action anywhere in WGS_Research.md, WGS_Valuation.md or WGS_Trade_Construction.md. The two 2025 payer-side events (AAP first-line recommendation, 2025Q2; FDA Breakthrough Device Designation for ExomeDx/GenomeDx, 2025Q3) have already happened — they are inputs to contracting, not scheduled catalysts. The Medicaid expansions (Texas, Maine, Arkansas, ~4.9m patients) were disclosed in the Q1-2026 release as completed. No forward reimbursement date has been invented to fill this gap. |
| Any clinical readout with a date | NONE EXISTS | ClinicalTrials.gov query.spons=GeneDx returns zero GeneDx-sponsored studies. The gNBS programmes are third-party-sponsored and the file records no primary-completion or readout dates for them. Inventing one would be inventing the company's most-promoted long-duration option. |
| Q3-2026, Q4-2026 and FY2026 exact report dates | NOT ANNOUNCED | Estimated in §2 from the prior-year cadence, with the basis stated in the row. Confirm each against company IR when announced. |
| FINRA settlement dates | NOT IN FILE | Cadence (semi-monthly) is known and used; the individual dates are not in the source documents and are not guessed. |
| Borrow fee / recall risk | NOT OBTAINABLE | Not available from any free source used in this memo. The ~10%/yr figure in Gate 4 is an explicitly-labelled assumption derived from the 30.79%-of-float profile, and the decision was tested for sensitivity to it. |
| Blackstone term-loan covenants and any dated test | NOT DISCLOSED | The 2026-02-27 8-K records a $100.0m Blackstone Life Sciences term loan and a $6.6m extinguishment loss on the Perceptive refinancing. Terms are not disclosed — which is also why the 10.0% pre-tax cost of debt in the WACC is flagged as an estimate. |
| Investor days, conference presentations, product launches | NONE IN FILE | No such event appears in any source document. None has been added. |
6. Next scheduled review
2026-08-04 — the trading day after Q2-2026. One computation decides the next move, and it takes minutes:
- ASP = Q2 E&G revenue ÷ Q2 E&G volume. Compare to $3,296 (Q1 actual), ~$3,333 (guided) and $3,506 (the H2 requirement).
- Guidance action — raised, reaffirmed, or cut again; and whether the H2 step-up is defended with a named mechanism.
- DSO from the Q2 10-Q balance sheet, extending the 36 → 48 → 43 → 48 → 57 → 68 day series.
Second review: ~late October 2026 (Q3-2026, date not announced). By then two of the two H2 quarters that carry the disputed +5.7% ASP step-up will have printed, and the variant is settled arithmetically rather than argumentatively.
Standing reminder from Trade §5: the reason not to act on 3 August is that the information is free one week later. The reason not to act after 3 August is that confirming the mechanism does not fix Gate 4 or Gate 5 — conversion needs the price and the crowding to move too, and all three conditions are specified in §3.